These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 16524539)

  • 1. Metabolic modulation of myocardial ischemia.
    Jani S; Bergmann SR
    Curr Cardiol Rep; 2006 Mar; 8(2):123-30. PubMed ID: 16524539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin therapy as an adjunct to reperfusion after acute coronary ischemia: a proposed direct myocardial cell survival effect independent of metabolic modulation.
    Sack MN; Yellon DM
    J Am Coll Cardiol; 2003 Apr; 41(8):1404-7. PubMed ID: 12706939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of metabolically active drugs in the management of ischemic heart disease.
    Schofield RS; Hill JA
    Am J Cardiovasc Drugs; 2001; 1(1):23-35. PubMed ID: 14728049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fatty acid oxidation inhibitors in the management of chronic complications of atherosclerosis.
    Folmes CD; Clanachan AS; Lopaschuk GD
    Curr Atheroscler Rep; 2005 Feb; 7(1):63-70. PubMed ID: 15683605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment.
    Lee L; Horowitz J; Frenneaux M
    Eur Heart J; 2004 Apr; 25(8):634-41. PubMed ID: 15084367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malonyl coenzyme a decarboxylase inhibition protects the ischemic heart by inhibiting fatty acid oxidation and stimulating glucose oxidation.
    Dyck JR; Cheng JF; Stanley WC; Barr R; Chandler MP; Brown S; Wallace D; Arrhenius T; Harmon C; Yang G; Nadzan AM; Lopaschuk GD
    Circ Res; 2004 May; 94(9):e78-84. PubMed ID: 15105298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Malonyl-CoA decarboxylase inhibition as a novel approach to treat ischemic heart disease.
    Lopaschuk GD; Stanley WC
    Cardiovasc Drugs Ther; 2006 Dec; 20(6):433-9. PubMed ID: 17136490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced preservation of acutely ischemic myocardium using glucose-insulin-potassium solutions.
    Lazar HL
    J Card Surg; 1994 May; 9(3 Suppl):474-8. PubMed ID: 8069039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac metabolism in ischemic heart disease.
    Opie LH
    Arch Mal Coeur Vaiss; 1999 Dec; 92(12):1755-60. PubMed ID: 10665328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic therapy for the treatment of ischemic heart disease: reality and expectations.
    Wang W; Lopaschuk GD
    Expert Rev Cardiovasc Ther; 2007 Nov; 5(6):1123-34. PubMed ID: 18035928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection of ischemic hearts perfused with an anion exchange inhibitor, DIDS, is associated with beneficial changes in substrate metabolism.
    Ramasamy R; Hwang Y; Bakr S; Bergmann SR
    Cardiovasc Res; 2001 Aug; 51(2):275-82. PubMed ID: 11470467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Abnormalities of myocardial lipid metabolism and advances of drug intervention in acute myocardial ischemia].
    Hu ZW
    Sheng Li Ke Xue Jin Zhan; 1984 Jan; 15(1):35-40. PubMed ID: 6151251
    [No Abstract]   [Full Text] [Related]  

  • 13. Metabolic intervention for the ischemic and post-ischemic heart.
    Svedjeholm R; Håkanson E; Szabó Z
    Wien Klin Wochenschr; 1999 Jul; 111(13):501-11. PubMed ID: 10444803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of ischemia-induced electrophysiologic abnormalities by glucose-insulin infusion.
    Bekheit S; Isber N; Jani H; Butrous G; Boutjdir M; el-Sherif N
    J Am Coll Cardiol; 1993 Oct; 22(4):1214-22. PubMed ID: 8409063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation by carnitine of myocardial fatty acid and carbohydrate metabolism under normal and pathological conditions.
    Calvani M; Reda E; Arrigoni-Martelli E
    Basic Res Cardiol; 2000 Apr; 95(2):75-83. PubMed ID: 10826498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic imaging in myocardial ischemia and heart failure.
    Knuuti J; Tuunanen H
    Q J Nucl Med Mol Imaging; 2010 Apr; 54(2):168-76. PubMed ID: 20588213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fatty acid oxidation in the reperfused ischemic heart.
    Kantor PF; Dyck JR; Lopaschuk GD
    Am J Med Sci; 1999 Jul; 318(1):3-14. PubMed ID: 10408755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of metabolic modulators in ischemic heart disease: an overview.
    Kalra BS; Roy V
    J Clin Pharmacol; 2012 Mar; 52(3):292-305. PubMed ID: 21383339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trimetazidine-induced enhancement of myocardial glucose utilization in normal and ischemic myocardial tissue: an evaluation by positron emission tomography.
    Mody FV; Singh BN; Mohiuddin IH; Coyle KB; Buxton DB; Hansen HW; Sumida R; Schelbert HR
    Am J Cardiol; 1998 Sep; 82(5A):42K-49K. PubMed ID: 9737485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Myocardial metabolism and metabolic drugs].
    Olesova VM; Markatiuk OIu; Iurova IuIu; Obrezan AG
    Kardiologiia; 2013; 53(1):66-71. PubMed ID: 23548353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.